SM
NVCR icon

SG3 Management’s NovoCure NVCR Stock Holding History

SG3 Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,400
Closed -$469K – 128
2022
Q4 		$469K Buy
6,400
+5,400
+540% +$406K 0.07% 118
2022
Q3 		$76K Hold
1,000
– – 0.01% 238
2022
Q2 		$70K Hold
1,000
– – 0.01% 340
2022
Q1 		$83K Sell
1,000
-19,000
-95% -$1.4M ﹤0.01% 843
2021
Q4 		$1.5M Buy
20,000
+10,000
+100% +$1M 0.03% 396
2021
Q3 		$1.16M Sell
10,000
-48,500
-83% -$7.33M 0.04% 429
2021
Q2 		$13M Buy
+58,500
New +$11.4M 0.46% 40

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

SG3 Management's NVCR Position: Q1 2022 in Review

SG3 Management sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 11,000 shares — an estimated $810K sold.

SG3 Management first reported a position in NVCR in Q4 2021 and held it in 1 quarter. The position peaked at $826K in Q4 2021. 309 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

  • SG3 Management reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 11,000 NovoCure shares in Q1 2022, an estimated $810K.
  • SG3 Management first reported a position in NovoCure in Q4 2021 and held it in 1 quarter.
  • SG3 Management's NovoCure position peaked at $826K in Q4 2021.
  • 309 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.